Regulatory Briefs: Comment Period For Masked Data Release Reopened; Studies On 510(k), Post-Market Programs
This article was originally published in The Gray Sheet
Executive Summary
FDA has reopened the comment period for its proposal to release masked trial data. The HHS Office of Inspector General released a study on FDA classification of class III pre-amendment devices. More regulatory news.
You may also be interested in...
NICE Guidance: Prostatic Implants, RF Ablation For Snoring, Transcranial Stimulation For Migraine, Arthroscopic Kneecap Surgery
The influential U.K. institute approves the use of prostatic urethral lift implants to treat urinary symptoms in men with benign prostatic hyperplasia, as well as radiofrequency ablation of the soft palate to treat snoring. Transcranial magnetic stimulation for migraine and arthroscopic trochleoplasty to treat patellar instability don’t fare as well.
Industry Questions Legality Of FDA Proposal To Release Masked Data
Device firms claim FDA does not have the legal authority to release masked and/or de-identified clinical trial data to researchers, as proposed in June. They also underscore the challenges in effectively masking device data, the risks to patient privacy and the hazards of analysis based on partial data.
FDA Calling For More PMAs Than 510(k)s In Final Set Of Preamendment Devices
“The Gray Sheet” reviewed CDRH’s proposed orders and final classification decisions on preamendment devices targeted by the 515 initiative. As of Aug. 5, FDA has proposed or finalized 14 PMAs, and proposed or finalized 10 products to be downclassified to class II with special controls.